Skip to main content

  • Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis — A real-world Indian experience (The OCTACOR India Study)

    • Posted: 06/13/2024
    • Author:

      John Jose, Asishkumar Mandalay, Manjunath N. Cholenahally, Ravindranath S. Khandenahally, Srinivas C. Budnur, Maulik Parekh, Ravinder S. Rao, Ashok Seth, Praveen Chandra, Rajneesh Kapoor, Praveer Agarwal, Atul Mathur, Vijay Kumar, Sadananda S. Kanchanahalli, Ajith S. Mullasari, Vijayakumar Subban, Uday B. Khanolkar, Sanjay Mehrotra, Manik Chopra, Rajendra K. Jain, Haresh Mehta, Rahul Gupta, Viveka Kumar, Bagirath Raghuraman, Naman Shastri, Hesham Elzomor, Osama Soliman and Sengottuvelu Gunasekaran

    • CRM2024News

    Abstract

    Purpose

    To evaluate the safety and effectiveness of the novel, next-generation Myval Octacor — Transcatheter Heart Valve (THV) in patients with severe, symptomatic, native aortic stenosis (AS).

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details